Revolution Medicines Inc.
RVMD | NASDAQ
$188.09
-$3.22 (-1.68%)
Nov 2, 2026, 1:38 PM ET · Market open
Market Data
Market Cap $40.31B
Enterprise Value $37.71B
Beta 1.40
Average Volume 2.12M
Shares Outstanding (Diluted) 210.89M
Shares Change YoY 12.09%
Institutional Ownership N/A
Exchange NASDAQ
ISIN US76155X1000
Price Performance
Price Change 1M -9.0%
Price Change 3M 3.1%
Price Change 6M 27.2%
Price Change YTD 136.2%
Price Change 1Y 217.0%
Price Change 3Y 748.8%
Price Change 5Y 468.6%
1M CAGR (ann.) 0.2%
1Y CAGR (ann.) 229.7%
5Y CAGR (ann.) 47.6%
All-Time CAGR 32.5%
Valuation
PE Ratio -21.59
Forward PE N/A
PEG Ratio 0.39
Forward PEG -0.32
PS Ratio N/A
Forward PS 33.30
PB Ratio 15.73
P/FCF Ratio -25.82
P/Adj. FCF Ratio -21.65
P/OCF Ratio -32.98
EV/Sales N/A
EV/EBIT -22.07
EV/EBITDA -22.24
EV/FCF -23.75
Earnings Yield -4.6%
FCF Yield -3.9%
Adj. FCF Yield -4.6%
Financial Health
Net Cash $3.45B
Total Debt $641.93M
Cash & Short-Term Investments $3.94B
Total Assets $4.32B
Current Ratio 11.38
Quick Ratio 11.38
Debt / Equity Ratio 0.25
Debt / EBITDA -0.38
Debt / FCF -0.40
OCF / Debt -2.46
Interest Coverage -27.42
Altman Z-Score 12.76
Piotroski F-Score 1
Margins & Profitability
Gross Profit Margin 0.0%
Operating Profit Margin 0.0%
EBITDA Margin 0.0%
Net Profit Margin 0.0%
FCF Margin N/A
Adj. FCF Margin N/A
SBC / Revenue 0.0%
SBC Impact (per share) -19.3%
Returns
Return on Assets -40.9%
Return on Equity -96.4%
Return on Invested Capital -40.8%
Return on Capital Employed -41.0%
Return on Tangible Assets -41.6%
Historical Growth (CAGR)
Revenue CAGR 3Y -150.0%
Revenue CAGR 5Y -73.0%
Revenue CAGR 10Y N/A
EPS CAGR 3Y -46.0%
EPS CAGR 5Y -28.6%
EPS CAGR 10Y N/A
FCF CAGR 3Y -57.0%
FCF CAGR 5Y -49.8%
FCF CAGR 10Y N/A
Analyst Forecasts
Analyst Rating Buy
Analyst Count 18
EPS Growth Next 3Y 55.2%
Revenue Growth Next 3Y N/A
Earnings Date Nov 4, 2026
EPS Estimate (next Q) -$2.35
EPS Growth Est (next Q) 46.0%
Revenue Est (next Q) $25.58M
Revenue Growth Est (next Q) N/A
Fair Value Estimates
Graham Number N/A
Graham Upside N/A
Lynch Fair Value N/A
Lynch Upside N/A
Price Target $253.47
Price Target Upside 32.5%
Cash Flow
Operating Cash Flow $-1.58B
Free Cash Flow $-1.59B
Adj. Free Cash Flow $-1.89B
FCF Per Share -$5.84
OCF Per Share -$5.80
OCF/S Ratio 0.0%
Income Statement
Revenue $0
Gross Profit $-9.24M
Operating Income $-1.63B
EBITDA $-1.7B
Net Income $-1.77B
EPS (Diluted) -$8.86
Revenue / Employee N/A
Profit / Employee $-2M
Employees 883
Add to Watchlist
Select watchlists to add or remove RVMD